Patents by Inventor Eric Topol

Eric Topol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130157347
    Abstract: Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).
    Type: Application
    Filed: July 6, 2012
    Publication date: June 20, 2013
    Applicants: Veridex, LLC, Scripps Health
    Inventors: Eric Topol, Samir Damani, Mark Connelly, Galla Chandra Rao
  • Patent number: 8133866
    Abstract: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: March 13, 2012
    Assignees: The Trustees of Columbia University in the City of New York, The Cleveland Clinic Foundation
    Inventors: David M. Stern, Ann Marie Schmidt, Steven Marso, Eric Topol, A. Michael Lincoff
  • Publication number: 20110294833
    Abstract: Genome-wide association studies have been used to elucidate genes and/or pathways related to diseases; however, this methodology has yet to be used to understand the phenotype of healthy aging and/or healthspan in humans.
    Type: Application
    Filed: May 27, 2010
    Publication date: December 1, 2011
    Applicant: SCRIPPS HEALTH
    Inventors: Eric Topol, Sarah Murray, Bradley Patay
  • Publication number: 20100292134
    Abstract: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels.
    Type: Application
    Filed: June 7, 2010
    Publication date: November 18, 2010
    Inventors: David M. Stern, Ann Marie Schmidt, Steven Marso, Eric Topol, A. Michael Lincoff
  • Patent number: 7732400
    Abstract: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: June 8, 2010
    Assignees: The Trustees of Columbia University in the City of New York, The Cleveland Clinic Foundation
    Inventors: David M. Stern, Ann Marie Schmidt, Steven Marso, Eric Topol, A. Michael Lincoff
  • Publication number: 20080171701
    Abstract: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels.
    Type: Application
    Filed: August 20, 2007
    Publication date: July 17, 2008
    Inventors: David M. Stern, Ann Marie Schmidt, Steven Marso, Eric Topol, A. Michael Lincoff
  • Publication number: 20060234245
    Abstract: A method of determining a person at risk of developing coronary artery disease includes detecting an alteration of at least one of an MEF2A gene, genes regulated by MEF2A transcription factor, or genes that regulate expression of MEF2A transcription factor of the patient. The alteration substantially reduces the transcription activity of the resulting MEF2A transcription factor.
    Type: Application
    Filed: August 27, 2004
    Publication date: October 19, 2006
    Inventors: Qing Wang, Eric Topol, Lejin Wang, Chun Fan